JPH09507053A - ニコチン禁断症状の治療のためのロベリンの使用 - Google Patents
ニコチン禁断症状の治療のためのロベリンの使用Info
- Publication number
- JPH09507053A JPH09507053A JP7512876A JP51287694A JPH09507053A JP H09507053 A JPH09507053 A JP H09507053A JP 7512876 A JP7512876 A JP 7512876A JP 51287694 A JP51287694 A JP 51287694A JP H09507053 A JPH09507053 A JP H09507053A
- Authority
- JP
- Japan
- Prior art keywords
- lobeline
- nicotine
- dosage form
- sublingual
- withdrawal symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 92
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229960002715 nicotine Drugs 0.000 title claims abstract description 92
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title claims description 33
- 238000011282 treatment Methods 0.000 title claims description 17
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 claims abstract description 92
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 claims abstract description 85
- 229930013610 lobeline Natural products 0.000 claims abstract description 85
- 229960002339 lobeline Drugs 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000006190 sub-lingual tablet Substances 0.000 claims abstract description 28
- 230000001154 acute effect Effects 0.000 claims abstract description 8
- 230000000717 retained effect Effects 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims description 58
- 210000004877 mucosa Anatomy 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 21
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 229940098466 sublingual tablet Drugs 0.000 claims description 15
- 239000012458 free base Substances 0.000 claims description 9
- 230000007774 longterm Effects 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 6
- 229940124535 smoking cessation aid Drugs 0.000 abstract description 4
- 230000000391 smoking effect Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 235000019504 cigarettes Nutrition 0.000 description 19
- GRZMOSSVIPFGFF-GNJLJDPWSA-N 2-[(2r,6s)-6-[(2s)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1.C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 GRZMOSSVIPFGFF-GNJLJDPWSA-N 0.000 description 13
- 230000005586 smoking cessation Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000208125 Nicotiana Species 0.000 description 11
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 235000019505 tobacco product Nutrition 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 206010012335 Dependence Diseases 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 206010057852 Nicotine dependence Diseases 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000820 nonprescription drug Substances 0.000 description 6
- 239000000779 smoke Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 235000019788 craving Nutrition 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- -1 β-hydroxyphenethyl Chemical group 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000009223 counseling Methods 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- 206010059612 Tobacco withdrawal symptoms Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000019506 cigar Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008370 chocolate flavor Substances 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical group CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 2
- 238000002670 nicotine replacement therapy Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BDEDPKFUFGCVCJ-UHFFFAOYSA-N 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde Chemical compound O=C1OC(O)CC(C(C=O)=C2O)=C1C1=C2CC(C)(C)C1 BDEDPKFUFGCVCJ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 241000968111 Lobelia inflata Species 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000135194 Pione Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 241001437644 Salmonella enterica subsp. enterica serovar Kentucky Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Degasification And Air Bubble Elimination (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14430993A | 1993-10-28 | 1993-10-28 | |
| US08/144,309 | 1993-10-28 | ||
| US08/145,203 | 1993-10-28 | ||
| US08/145,203 US5414005A (en) | 1993-10-28 | 1993-10-28 | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation |
| PCT/US1994/012442 WO1995011679A1 (en) | 1993-10-28 | 1994-10-28 | Use of lobeline for the treatment of nicotine withdrawal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09507053A true JPH09507053A (ja) | 1997-07-15 |
Family
ID=26841884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7512876A Ceased JPH09507053A (ja) | 1993-10-28 | 1994-10-28 | ニコチン禁断症状の治療のためのロベリンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0725640A1 (enExample) |
| JP (1) | JPH09507053A (enExample) |
| AU (2) | AU8096094A (enExample) |
| CA (1) | CA2174747A1 (enExample) |
| TW (1) | TW261531B (enExample) |
| WO (2) | WO1995011679A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509705A (ja) * | 2003-10-28 | 2007-04-19 | アルザ・コーポレーシヨン | タバコ使用頻度を低下させる方法および装置 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE326468T1 (de) | 1996-10-30 | 2006-06-15 | Pfizer | Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie |
| ES2141024B1 (es) * | 1997-10-03 | 2000-10-16 | Manzanares Jesus Mari Gonzalez | Preparado de accion antinicotinica. |
| GB2376884A (en) * | 2001-06-26 | 2002-12-31 | Peter Hajek | Helping smokers stop |
| CN103284319A (zh) * | 2013-06-20 | 2013-09-11 | 昌宁德康生物科技有限公司 | 一种金雀花碱替代尼古丁口腔雾化液及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1017032A (en) * | 1963-12-12 | 1966-01-12 | Aerosmoke Ltd | Aerosol compositions |
| GB1056214A (en) * | 1964-05-21 | 1967-01-25 | Leo Baum | Compositions containing lobeline sulphate |
| CH658594A5 (de) * | 1982-02-22 | 1986-11-28 | Bruss Ni Sanitarno Gigieniches | Arzneipraeparat mit antinikotinwirkung und verfahren fuer seine herstellung. |
| US4665069A (en) * | 1985-04-02 | 1987-05-12 | Barnett Rosenberg | Analgesic composition and method of relieving pain |
| GB2230439A (en) * | 1989-04-20 | 1990-10-24 | Alec Stanley Walter Shaw | Nicotine lozenges |
-
1993
- 1993-11-08 TW TW082109338A patent/TW261531B/zh active
-
1994
- 1994-10-28 EP EP95901081A patent/EP0725640A1/en not_active Withdrawn
- 1994-10-28 AU AU80960/94A patent/AU8096094A/en not_active Abandoned
- 1994-10-28 CA CA002174747A patent/CA2174747A1/en not_active Abandoned
- 1994-10-28 WO PCT/US1994/012442 patent/WO1995011679A1/en not_active Ceased
- 1994-10-28 JP JP7512876A patent/JPH09507053A/ja not_active Ceased
- 1994-10-28 AU AU10456/95A patent/AU1045695A/en not_active Abandoned
- 1994-10-28 WO PCT/US1994/012441 patent/WO1995011678A1/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509705A (ja) * | 2003-10-28 | 2007-04-19 | アルザ・コーポレーシヨン | タバコ使用頻度を低下させる方法および装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0725640A1 (en) | 1996-08-14 |
| AU8096094A (en) | 1995-05-22 |
| WO1995011679A1 (en) | 1995-05-04 |
| WO1995011678A1 (en) | 1995-05-04 |
| TW261531B (enExample) | 1995-11-01 |
| AU1045695A (en) | 1995-05-22 |
| CA2174747A1 (en) | 1995-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| US5783207A (en) | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine | |
| JP5845194B2 (ja) | ニコチン含有ソフトゼラチントローチ | |
| Gourlay et al. | Antismoking products | |
| US5055478A (en) | Method for stopping smoking | |
| JP2009539895A (ja) | ＡＣｈＥ−ＮＭＤＡ組み合わせウェーハ | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| US20100256197A1 (en) | Nicotine Dissolving Film With Or Without Menthol | |
| EP2029098A2 (de) | Raucherentwöhnungs-kombinationswafer | |
| JPH09507053A (ja) | ニコチン禁断症状の治療のためのロベリンの使用 | |
| WO2018169387A1 (en) | Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction | |
| WO1995011678A9 (en) | Use of nicotine substitutes for the treatment of nicotine withdrawal | |
| US3989823A (en) | Compositions for combating nicotinism in man | |
| US20050045197A1 (en) | Multiple drug delivery system & method | |
| BR102020025389A2 (pt) | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da dependência a nicotina e processo | |
| Wongwiwatthananukit et al. | Smoking cessation: Part 2—pharmacologic approaches | |
| Jain et al. | Nicotine chewing gum remedial approach against smoking and chewing habits | |
| US20040115244A1 (en) | Methods and compositions for nicotine replacement therapy | |
| Jarvis | Tobacco smoking: an everyday drug | |
| Ryan | Smoking cessation | |
| ARORA et al. | Targeting Nicotine Addiction-The Possibility of a Healthier Future | |
| Baker | Stop smoking please-for all our sakes! | |
| Pfister | Oral transmucosal delivery of nicotine: smoking cessation therapy | |
| WO1996029076A2 (en) | Treatment of inflammatory bowel disorders with cotinine | |
| Srivastava et al. | Journal of Dental Herald |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040210 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040315 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040330 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20040727 |